143 related articles for article (PubMed ID: 6661467)
21. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
Wright CI; Geula C; Mesulam MM
Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355
[TBL] [Abstract][Full Text] [Related]
22. Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.
Appleyard ME; McDonald B
J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1074-8. PubMed ID: 1469405
[TBL] [Abstract][Full Text] [Related]
23. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid acetylcholinesterase in neuropsychiatric disorders.
Davis KL; Hollister LE; Livesey J; Berger PA
Psychopharmacology (Berl); 1979 May; 63(2):155-9. PubMed ID: 157494
[TBL] [Abstract][Full Text] [Related]
25. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid.
Vawter MP; Dillon-Carter O; Tourtellotte WW; Carvey P; Freed WJ
Exp Neurol; 1996 Dec; 142(2):313-22. PubMed ID: 8934562
[TBL] [Abstract][Full Text] [Related]
26. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
[TBL] [Abstract][Full Text] [Related]
27. Cholinesterases in cerebrospinal fluid. A longitudinal study in Alzheimer disease.
Elble R; Giacobini E; Scarsella GF
Arch Neurol; 1987 Apr; 44(4):403-7. PubMed ID: 3827696
[TBL] [Abstract][Full Text] [Related]
28. Increased cerebrospinal fluid cortisol level in Alzheimer's disease is not related to depression.
Hoogendijk WJ; Meynen G; Endert E; Hofman MA; Swaab DF
Neurobiol Aging; 2006 May; 27(5):780.e1-780.e2. PubMed ID: 16198445
[TBL] [Abstract][Full Text] [Related]
29. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology.
Berson A; Knobloch M; Hanan M; Diamant S; Sharoni M; Schuppli D; Geyer BC; Ravid R; Mor TS; Nitsch RM; Soreq H
Brain; 2008 Jan; 131(Pt 1):109-19. PubMed ID: 18056160
[TBL] [Abstract][Full Text] [Related]
30. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia.
Wallin A; Sjögren M; Blennow K; Davidsson P
Dement Geriatr Cogn Disord; 2003; 16(4):200-7. PubMed ID: 14512714
[TBL] [Abstract][Full Text] [Related]
31. Acetylcholinesterase activity in ventricular and cisternal CSF of dogs: effect of chlorpromazine.
Bareggi SR; Giacobini E
J Neurosci Res; 1978; 3(5-6):335-9. PubMed ID: 739556
[TBL] [Abstract][Full Text] [Related]
32. Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease.
Sáez-Valero J; Barquero MS; Marcos A; McLean CA; Small DH
J Neurol Neurosurg Psychiatry; 2000 Nov; 69(5):664-7. PubMed ID: 11032625
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
[TBL] [Abstract][Full Text] [Related]
34. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.
Ahmed N; Ahmed U; Thornalley PJ; Hager K; Fleischer G; Münch G
J Neurochem; 2005 Jan; 92(2):255-63. PubMed ID: 15663474
[TBL] [Abstract][Full Text] [Related]
35. A highly sensitive gold-nanoparticle-based assay for acetylcholinesterase in cerebrospinal fluid of transgenic mice with Alzheimer's disease.
Liu D; Chen W; Tian Y; He S; Zheng W; Sun J; Wang Z; Jiang X
Adv Healthc Mater; 2012 Jan; 1(1):90-5. PubMed ID: 23184691
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease.
Johansson P; Almqvist EG; Johansson JO; Mattsson N; Andreasson U; Hansson O; Wallin A; Blennow K; Zetterberg H; Svensson J
PLoS One; 2013; 8(11):e81989. PubMed ID: 24312390
[TBL] [Abstract][Full Text] [Related]
37. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease.
Sáez-Valero J; Sberna G; McLean CA; Small DH
J Neurochem; 1999 Apr; 72(4):1600-8. PubMed ID: 10098867
[TBL] [Abstract][Full Text] [Related]
38. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma.
Peskind ER; Wingerson D; Pascualy M; Thal L; Veith RC; Dorsa DM; Bodenheimer S; Raskind MA
Biol Psychiatry; 1995 Oct; 38(8):532-8. PubMed ID: 8562665
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid choline, and acetylcholinesterase activity in familial vs. non-familial Alzheimer's disease patients.
Kumar V; Giacobini E
Arch Gerontol Geriatr; 1988 Jun; 7(2):111-7. PubMed ID: 3415394
[TBL] [Abstract][Full Text] [Related]
40. Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease.
Sirviö J; Kutvonen R; Soininen H; Hartikainen P; Riekkinen PJ
J Neural Transm; 1989; 75(2):119-27. PubMed ID: 2918304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
